Treatment possibilities of ipilimumab-induced thrombocytopenia-case study and literature review

Japanese Journal of Clinical Oncology

Volumn 45, Issue 4, 2015, Pages 381-384

  Kopecký, Jindřich ^a   Trojanová, Petronela ^a   Kubeček, Ondřej ^a   Kopecký, Otakar ^b  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b Regional Hospital Náchod   (Czech Republic)

Author keywords

Ipilimumab; Melanoma; Thrombocytopenia

Indexed keywords

CISPLATIN; CORTICOSTEROID; COTRIMOXAZOLE; DACARBAZINE; INTERFERON; IPILIMUMAB; METHYLPREDNISOLONE; OMEPRAZOLE; VINBLASTINE; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BONE MARROW BIOPSY; BONE MARROW EXAMINATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASE REPORT; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG PULSE THERAPY; HOSPITAL DISCHARGE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; MALE; METASTATIC MELANOMA; PROPHYLAXIS; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; CHEMICALLY INDUCED; MELANOMA; MIDDLE AGED; SECONDARY; SKIN NEOPLASMS; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84926435450     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyu222     Document Type: Article

References (13)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
3. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006;18:206-13.
4. Tarhini A. Immune-mediated adverse events with ipilimumab-associated CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) 2013;2013:857519.
5. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691-7.
6. Momtaz P, Lacouture ME, Chapman PB. Current choices and strategies in the treatment of metastatic. Melanoma Letter Spring 2014;32:1.
7. Ahmad S, Lewis M, Corrie P, Iddawela M. Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma. J Oncol Pharm Pract 2012;8:287-92.
8. Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug induced immune thrombocytopenia: pathogenesis, diagnosis and management. J Thromb Haemost 2009;7:911-18.
9. Stasi R, Evangelista ML, Stipa E, et al. Idiopathic thrombocytopenic purpura: current concept in pathophysiology and management. Thromb Haemost 2008;99:4-13.
10. Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003; 349:831-6.
11. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-86.
12. Imbach P,Wagner HP, Berchtold W, et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 1985;2:464-8.
13. Imbach P. Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases. a historical review. Swiss Med Wkly 2012;142:w13593.